Beat AML, LLC
Beat AML, LLC
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Recruiting | Phase 2 / Phase 3 | 2026-09-03 | NCT03013998 | |
| Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-09-02 | NCT06652438 |